A Phase 4 interventional study of Metronidazole gel 1% in Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-29.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Rosacea by Galderma Group AG — none open to participants now, none under way, none of them phase 3. Rosacea · Galderma Group AG.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 4, and was the 3rd registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 28 studies in Rosacea by Galderma Group AG is open now. The open studies under Rosacea, anywhere →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2006.
This study's enrollment of 26 is below the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 198 across the 24 interventional studies, 211 across the 4 observational. Of the 28 that completed or were terminated, 21 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Rosacea by Galderma Group AG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.
This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Metronidazole gel 1%
Applied once to a test site on the right or left cheek (as determined by a randomization design)
Also known as: MetroGel® 1%
Six replicate Corneometer CM 825 measurements
Time frame: 8 hours
Adverse events
Time frame: 1 day
The record gives a start of Aug 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole